BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer |
| April 12, 2021 | April 2021 Bond Updates |
|
LUND, Sweden, April 12, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data from a phase I dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) at the... |
| View more at: https://www.prnewswire.com:443/news-releases/bioinvents-partner-oncurious-nv-presents-phase-i-data-on-tb-403-in-pediatric-cancer-301266424.html |